CLINICAL_TRIALS
trial_result
· 2013-01-21
Clinical Trial Update: Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis [Phase 2]
Summary
Phase 2 trial update determining the maximum tolerated dose of caspofungin in patients with invasive aspergillosis; results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Cologne | Conditions: Invasive Aspergillosis | Phase 2 | Status: COMPLETED | Results posted: 2013-01-21